Stocktube video
13/10/2011

Fusion IP reports a full-year profit and revenue up 35%

View full size
Additional Information
Market: AIM
Sector: Technology Hardware & Equipment
EPIC: FIP
Latest Price: 52.50p  (1.94% Ascending)
52-week High: 77.50p
52-week Low: 21.50p
Market Cap: 38.24M
1 year chart
1 day chart
Watchlist/Portfolio

Add to watchlist:

Only registered members can add into watchlist !

Register here !

Fusion IP owns the rights to 100% of the university-owned research generated at two of the UK's leading universities – The University of Sheffield and Cardiff University. These exclusive partnerships enable us to invest in some the world's most advanced and exciting science, turning world class research into business through the creation of a growing portfolio of companies, in fields as varied as drug discovery, alternative energy and engineering.

All RNS Press Releases

RNS Release - Mesuro - Sales

2nd Feb 2012, 7:00 am
RNS Number : 6479W
Fusion IP PLC
02 February 2012
 



 For immediate release

02 February 2012

 

FUSION IP PLC

("Fusion IP" or "the Company")

 "Mesuro secures last quarter orders of $1.25 million for its revolutionary RF systems"

 

Fusion IP plc (AIM: FIP), the university IP commercialisation company that turns world class research into business, is pleased to announce that Mesuro, the Cardiff University spin-out which sells RF testing equipment and device measurement services to the semiconductor industry, has announced today that it took orders for $1.25million of new sales of its revolutionary RF equipment technology in the last quarter of the year..

 

Richard Emsley, CEO of Mesuro, commented:

 

"These sales, which have been made to three global customers, all of whom cannot be disclosed for commercial reasons, demonstrate the huge potential of Mesuro's RF technology, which enables device manufacturers to obtain the very highest performance from their designs, maximise device efficiency, reduce power consumption and decrease time to market. We look forward to accelerating the growth of the company in 2012."

 

David Baynes, CEO of Fusion IP, commented:

 

"Mesuro is in a transformational year and these sales should be a stepping stone for the company to secure significant sales in 2012. We look forward to working with Mesuro to converting its highly promising pipeline in the coming year."

 

Fusion has a 47% shareholding in Mesuro.

 

Ann Casey, Investment Executive at investor Finance Wales, commented:

 

"These new contracts are excellent news and a perfect start to 2012 for Mesuro.  They represent a big step forward for the company and prove there is a significant market for Mesuro's innovative technology.  We're looking forward to seeing Mesuro's order book continue to grow during the year."

 

For further information please contact:

 

Fusion IP

+44 (0) 114 275 5555

David Baynes, CEO

Stuart Gall (Commercial Director and Press relations)

 


Mesuro

+44 (0) 7730 289 459

Richard Emsley, CEO


Seymour Pierce

+44 (0) 20 7107 8000

Freddy Crossley , Corporate Finance

Catherine Leftley, Corporate Finance

David Banks, Corporate Broking


 

 

 

About Fusion IP

Fusion IP plc (Fusion) was established in 2002 to commercialise university-generated intellectual property.  It has long-term exclusive agreements with two of the UK's leading research intensive universities, the University of Sheffield and Cardiff University, giving it exclusive access to a combined R&D spend of over £185m a year. 

Fusion's first agreement was a ten-year exclusive arrangement with the University of Sheffield, giving it the right to commercialise (through the creation of spin-out companies and licensing) research, owned by the University, initially in the area of medical life sciences. This agreement was expanded in July 2008 to include all non-life science research-generated IP such as energy, engineering and electronics. Fusion has significant shareholdings in a portfolio of University of Sheffield spin-out companies including Simcyp, Magnomatics, Diurnal and Phase Focus.

In January 2007, Fusion completed a ten year exclusive agreement with Cardiff University, also giving it the right to commercialise (through the creation of spin-out companies) Cardiff University's research-generated IP.  Fusion has significant shareholdings in a portfolio of Cardiff University spin-out companies including Mesuro, Asalus and MedaPhor.

On 2 December 2009 Fusion announced that it had raised approximately £3.2 million through a fund raising and that as a result, IP Group held approximately 19.8% of Fusion. Fusion has also entered into a Co-Investment Agreement with IP Group, in which IP Group has the right to acquire for cash, 20% of Fusion's equity in any new portfolio company. As Fusion normally owns 60% of any new portfolio company at start-up, IP Group's shareholding would normally equate to a 12% stake in the new portfolio company.

Fusion IP also has a Memorandum of Understanding with Finance Wales, the provider of commercial funding to Wales-based SMEs, which outlines a strategy of co-investment in opportunities arising from the Cardiff Agreement.

On 8 November 2011 Fusion announced that it had raised approximately £5 million through a fundraising with existing and new institutional investors. As a result of this IP Group holds an interest in approximately 26% of Fusion.

For more information visit: www.fusionip.co.uk

About Mesuro

 

Headquartered in Cardiff, UK, Mesuro focuses on commercialising RF test and measurement technologies resulting from Cardiff University's world-renowned Centre for High Frequency Engineering. Mesuro's measurement solutions overcome many of the limitations inherent in traditional design and testing processes by providing complete information and control of high frequency signals of the circuits under test. This allows for the development of an integrated development process that streamlines the development and testing cycle and reduces time to market. In addition to offering turnkey active load pull solutions, Mesuro also offers a wide range of testing services.

 

For more information, visit: www.mesuro.com

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCMMGGZRMMGZZM

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.